Healthcare provider profile · identity verified

Benjamin Douglas Womack, MD

Internal Medicine · NASHVILLE, TN · NPI 1174670962

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	757	203
Losartan Potassium	Losartan Potassium	404	109
Amlodipine Besylate	Amlodipine Besylate	368	105
Rosuvastatin Calcium	Rosuvastatin Calcium	298	89
Levothyroxine Sodium	Levothyroxine Sodium	287	74
Omeprazole	Omeprazole	257	74
Lisinopril	Lisinopril	243	68
Hydrochlorothiazide	Hydrochlorothiazide	237	78
Gabapentin	Gabapentin	225	47
Tamsulosin Hcl	Tamsulosin Hcl	209	57
Eliquis	Apixaban	188	43
Metoprolol Succinate	Metoprolol Succinate	157	38
Carvedilol	Carvedilol	146	34
Metformin Hcl Er	Metformin Hcl	140	38
Pantoprazole Sodium	Pantoprazole Sodium	135	45
Metformin Hcl	Metformin Hcl	134	36
Sertraline Hcl	Sertraline Hcl	134	36
Finasteride	Finasteride	123	30
Furosemide	Furosemide	117	36
Trazodone Hcl	Trazodone Hcl	115	36
Duloxetine Hcl	Duloxetine Hcl	112	27
Fluticasone Propionate	Fluticasone Propionate	103	35
Pravastatin Sodium	Pravastatin Sodium	102	25
Allopurinol	Allopurinol	95	23
Simvastatin	Simvastatin	88	23
Potassium Chloride	Potassium Chloride	87	26
Glimepiride	Glimepiride	86	21
Donepezil Hcl	Donepezil Hcl	78	22
Spironolactone	Spironolactone	78	24
Azelastine Hcl	Azelastine Hcl	77	28
Metoprolol Tartrate	Metoprolol Tartrate	76	21
Ozempic	Semaglutide	69	18
Enalapril Maleate	Enalapril Maleate	64	16
Fluoxetine Hcl	Fluoxetine Hcl	63	16
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	58	45
Meloxicam	Meloxicam	58	21
Mounjaro	Tirzepatide	58	suppressed
Bupropion Xl	Bupropion Hcl	55	20
Montelukast Sodium	Montelukast Sodium	55	13
Telmisartan	Telmisartan	54	15
Citalopram Hbr	Citalopram Hydrobromide	52	11
Synthroid	Levothyroxine Sodium	49	15
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	45	12
Ezetimibe	Ezetimibe	44	18
Jardiance	Empagliflozin	44	11
Valsartan	Valsartan	44	17
Xarelto	Rivaroxaban	42	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	40	13
Trulicity	Dulaglutide	40	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	40	17
Albuterol Sulfate Hfa	Albuterol Sulfate	39	21
Cephalexin	Cephalexin	39	29
Alendronate Sodium	Alendronate Sodium	38	12
Doxycycline Hyclate	Doxycycline Hyclate	37	32
Escitalopram Oxalate	Escitalopram Oxalate	37	suppressed
Eplerenone	Eplerenone	35	suppressed
Nifedipine Er	Nifedipine	35	12
Mirtazapine	Mirtazapine	34	suppressed
Propranolol Hcl	Propranolol Hcl	33	12
Clopidogrel	Clopidogrel Bisulfate	32	11
Quetiapine Fumarate	Quetiapine Fumarate	32	suppressed
Bupropion Hcl Sr	Bupropion Hcl	31	suppressed
Famotidine	Famotidine	30	suppressed
Methylprednisolone	Methylprednisolone	30	26
Triamcinolone Acetonide	Triamcinolone Acetonide	30	20
Estradiol	Estradiol	29	13
Paxlovid	Nirmatrelvir/Ritonavir	29	28
Ramipril	Ramipril	29	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	29	11
Farxiga	Dapagliflozin Propanediol	28	suppressed
Warfarin Sodium	Warfarin Sodium	28	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	27	suppressed
Ipratropium Bromide	Ipratropium Bromide	26	11
Valacyclovir	Valacyclovir Hcl	26	12
Irbesartan	Irbesartan	25	suppressed
Nitroglycerin	Nitroglycerin	25	17
Acyclovir	Acyclovir	24	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	24	suppressed
Clobetasol Propionate	Clobetasol Propionate	23	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	23	suppressed
Azithromycin	Azithromycin	22	17
Celecoxib	Celecoxib	22	suppressed
Lorazepam	Lorazepam	22	suppressed
Pregabalin	Pregabalin	21	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	20	suppressed
Myrbetriq	Mirabegron	20	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	19	suppressed
Paroxetine Hcl	Paroxetine Hcl	19	suppressed
Chlorthalidone	Chlorthalidone	17	suppressed
Diclofenac Sodium	Diclofenac Sodium	17	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	16	suppressed
Buspirone Hcl	Buspirone Hcl	15	suppressed
Fluconazole	Fluconazole	15	12
Ketoconazole	Ketoconazole	15	suppressed
Ondansetron Odt	Ondansetron	15	14
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	14	suppressed
Indapamide	Indapamide	14	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	14	suppressed
Memantine Hcl	Memantine Hcl	14	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	14	suppressed
Atenolol	Atenolol	13	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	13	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	13	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	13	suppressed
Methocarbamol	Methocarbamol	13	suppressed
Mupirocin	Mupirocin	13	12
Nystatin	Nystatin	13	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	13	suppressed
Prednisone	Prednisone	13	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	12	suppressed
Glipizide Er	Glipizide	12	suppressed
Oxcarbazepine	Oxcarbazepine	12	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	12	suppressed
Clonidine Hcl	Clonidine Hcl	11	suppressed
Dextroamphetamine-Amphet Er	Dextroamphetamine/Amphetamine	11	suppressed
Hydralazine Hcl	Hydralazine Hcl	11	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	11	suppressed
Meclizine Hcl	Meclizine Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error